Previous 10 | Next 10 |
2024-02-12 17:35:56 ET More on VistaGen Therapeutics VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond Vistagen shares move up after Jefferies upgrade Vistagen climbs as Stifel launches at Buy on anxiety prospects Seeking Alpha’s Quant Rati...
2024-02-07 07:38:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Entering 2024, a shift toward optimism emerges in the market, with eased monetary policies potentially opening doors for penny stocks to rebound. Savvy investors, drawn to overlooked opport...
Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast to report results for its fiscal year 2024 third quarter end...
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5...
Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...
2024-01-26 09:04:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and lo...
Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received a notice of intention to grant a patent...
Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demonstrate AV-101’s robust effects similar to gabapentin but with a better side effect profile Phase 1 data demonstrate AV-101 is well-tolerated, with no m...
2023-12-22 18:24:37 ET Summary Positive results achieved in phase 3 PALISADE-2 study for Fasedienol, a potential new treatment for social anxiety disorder. It is estimated that there are roughly 25 million people in the United States with this disorder. Itruvone is being advan...
2023-12-07 08:27:08 ET MicroAlgo ( MLGO ) +74% plans to establish a practice base to train graduate students for the university. Altisource Asset Management ( AAMC ) +23% Asset case against six defendants in suit v. BlackRock, Pimco can proceed. ...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, has announced that its management will present and host one-on-one meetings during the 2024 RBC Capital Markets Glo...
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the 2024 RBC Capital Market...